Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

Seattle Genetics, Inc.

today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL. Presentations will feature data from several corporate and investigator-sponsored trials with ADCETRIS® (brentuximab vedotin), including additional analyses from the phase 3 AETHERA clinical trial and updated data in frontline diffuse large B-cell lymphoma (DLBCL). In addition, the company's ADC collaborators, including Genentech (a member of the Roche Group), AbbVie, Genmab and Agensys (an affiliate of Astellas), will report data from clinical programs using Seattle Genetics' ADC technology. Seattle Genetics will also present preclinical data from its novel SEA-CD40 immuno-oncology candidate currently being evaluated in a phase 1 clinical trial. Seattle Genetics is evaluating its ADC technology broadly through ADCETRIS, proprietary pipeline and collaborator programs. The company is leading the field in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition, Seattle Genetics is building on expertise in empowered, targeted approaches for the treatment of cancer in advancing its proprietary sugar-engineered antibody (SEA) technology, a novel technology designed to increase the potency of monoclonal antibodies through glycoengineering which may lead to an improved antitumor immune response. Corporate, investigator and collaborator presentations are included below and full abstracts can be accessed on the ASCO website at abstracts.asco.org. Saturday, May 30, 2015 A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors (Seattle Genetics; Abstract #3074, poster presentation) A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC in patients with solid tumors (Genmab; Abstract #2570, poster presentation) Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers (Genmab; Abstract #3066, poster presentation) ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR) (AbbVie; Abstract #2510, poster presentation) STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC) (Genentech; Abstract #5029, poster presentation) Sunday, May 31, 2015 Multivariate analysis of PFS from the AETHERA trial: a phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL (Seattle Genetics; Abstract #8519, poster presentation) Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children's Oncology Group report (Investigator-sponsored; Abstract # 8544, poster presentation) Monday, June 1, 2015 Updated results of a phase 2 trial of brentuximab vedotin combined with RCHOP in frontline treatment of pts with high-intermediate/high-risk DLBCL (Seattle Genetics; Abstract #8506, oral presentation 11:21 a.m. CT) Quality of life EQ-5D results from the AETHERA trial: a phase 3 study of brentuximab vedotin consolidation following autologous stem cell transplant for HL (Seattle Genetics; Abstract #6568, poster presentation) Brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial (Investigator-sponsored; Abstract #8505, oral presentation 11:09 a.m. CT) Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level (Genentech; Abstract #8503, oral presentation 9:45 a.m. – 12:45 p.m. CT) Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM) (AbbVie; Abstract #2016, poster presentation) Tuesday, June 2, 2015 Ph 1 studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RCC) (Agensys; Abstract #2503, oral presentation 8:00 – 11:00 a.m. CT)